← All trials
NCT05032820
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2021
- Primary completion
- Apr 30, 2023
- Completion date
- Feb 28, 2025
- First posted
- Sep 2, 2021
- Last posted
- Oct 21, 2021
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical College of WisconsinLead sponsor
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
- Bristol-Myers SquibbCollaborator
- Medical College of WisconsinSponsor investigator
- Medical College of WisconsinStudy director
- Memorial Sloan-Kettering Cancer CenterOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Marrow Donor ProgramCollaborator
- Memorial Sloan-Kettering Cancer CenterOfficial
- Medical College of WisconsinOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.